15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 8 firms covering Agios Pharm, 5 rate it Buy or better, 3 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $32.00 to $55.00, a moderate spread. The average target of $41.25 sits 23% above the current $33.56. The rating mix has stayed broadly stable, with Buy-side ratings easing from 6 to 5 over recent months. On the fundamentals, the Street sees revenue growth near 131% this year and 108% next, consensus EPS building from about $-1.08 next quarter toward $-3.69 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 ratings
Moderate Buy
Strong Buy00%
Buy563%
Hold338%
Sell00%
Strong Sell00%
Based on 8 analysts giving stock ratings to Agios Pharm.
As of Sep, 5 of 8 firms rate AGIO a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
AGIO EPS & revenue forecast
EPS · NEXT QUARTER
$-1.08
Range $-1.53 – $-0.47 · 10 analysts · -41% YoY
Next period, 10 analysts expect Agios Pharm to earn $-1.08 a share (range $-1.53 – $-0.47), versus $-1.85 a year earlier. Full-year consensus is $-5.63, growing to $-3.69 the year after.
REVENUE · NEXT QUARTER
$63.2M
Range $53.5M – $86.4M · 10 analysts · +167% YoY
Revenue is expected to reach $63.2M (range $53.5M – $86.4M), +167.0% year-over-year. Full-year consensus is $182.5M, rising to $351.5M next year.
Top analysts covering Agios Pharm
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AGIO.
#1
Luca Issi
RBC Capital · Rank #1
Hold
$32.00-4.6% to target
Overall win rate
55%
+ Follow
#2
Andrew Berens
Leerink Partners · Rank #121
Buy
No targeton AGIO
Overall win rate
56%
+ Follow
#3
Greg Harrison
Scotiabank · Rank #179
Buy
$65.00+93.7% to target
Overall win rate
38%
+ Follow
#4
Gregory Renza
RBC Capital · Rank #213
Buy
$57.00+69.8% to target
Overall win rate
34%
+ Follow
#5
Emily Bodnar
HC Wainwright & Co. · Rank #399
Buy
$55.00+63.9% to target
Overall win rate
23%
+ Follow
AGIO stock forecast FAQ
What is AGIO's average 12-month price target?+
The 8 analysts with a live target average $41.25 for Agios Pharm over the next 12 months, ranging from a $55.00 high to a $32.00 low.
Is AGIO stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 8 analyst ratings, 5 are Buy or Strong Buy, 3 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for AGIO?+
The Street-high target is $55.00 (HC Wainwright & Co.), and the Street-low is $32.00 (RBC Capital). The average of all 8 active targets is $41.25.
How many Wall Street analysts cover AGIO?+
8 analysts have an active rating on Agios Pharm, and 8 firms carry a live 12-month price target.
Who is the most accurate analyst covering AGIO?+
Among analysts who currently cover AGIO, Luca Issi of RBC Capital has the strongest overall Quantellect track record (Rank #1). Their current call is Hold with a $32.00 target.
What is Agios Pharm's projected EPS for next quarter?+
The consensus estimate is $-1.08 per share (range $-1.53 – $-0.47) across 10 analysts. Full-year EPS is projected at $-5.63, rising to $-3.69 the following year.
How much revenue is Agios Pharm expected to report next quarter?+
Consensus revenue is $63.2M (range $53.5M – $86.4M). Full-year revenue is projected at $182.5M, growing to $351.5M next year.
Have analysts been upgrading or downgrading AGIO lately?+
As of Sep, 5 of 8 firms rate AGIO a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AGIO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
